Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2009 2
2010 2
2011 2
2015 3
2016 1
2017 2
2019 2
2020 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Anxiolytic-like effects of noribogaine in zebrafish.
Kalueff AV, Kaluyeva A, Maillet EL. Kalueff AV, et al. Among authors: maillet el. Behav Brain Res. 2017 Jul 14;330:63-67. doi: 10.1016/j.bbr.2017.05.008. Epub 2017 May 4. Behav Brain Res. 2017. PMID: 28479267
Noribogaine reduces nicotine self-administration in rats.
Chang Q, Hanania T, Mash DC, Maillet EL. Chang Q, et al. Among authors: maillet el. J Psychopharmacol. 2015 Jun;29(6):704-11. doi: 10.1177/0269881115584461. Epub 2015 May 20. J Psychopharmacol. 2015. PMID: 25995321 Free PMC article.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S. Family N, et al. Among authors: maillet el. Psychopharmacology (Berl). 2020 Mar;237(3):841-853. doi: 10.1007/s00213-019-05417-7. Epub 2019 Dec 18. Psychopharmacology (Berl). 2020. PMID: 31853557 Free PMC article. Clinical Trial.
Noribogaine is a G-protein biased κ-opioid receptor agonist.
Maillet EL, Milon N, Heghinian MD, Fishback J, Schürer SC, Garamszegi N, Mash DC. Maillet EL, et al. Neuropharmacology. 2015 Dec;99:675-88. doi: 10.1016/j.neuropharm.2015.08.032. Epub 2015 Aug 21. Neuropharmacology. 2015. PMID: 26302653 Free article.
16 results